Company: RVRC
Filing Date: 2025-12-12
Form Type: S-1/A
Source: 0001213900-25-121070
Chunk: 57

Company: Revium Rx.
Filing Date: 2025-12-12
Form: S-1/A
Chunk 57
---
 | $880,000 (approx. 20%)   |     | Salaries, legal, IP, audit, and other operating costs.                                     |     | Covered by proceeds; no additional funds required.  |

If we raise less than the full offering amount,
we intend to prioritize activities related to our lead program (Nano-Mupirocin), and delay or reduce certain planned expenditures, including
clinical trial initiation, until additional financing becomes available.

To fully execute the Phase 1 and 2 clinical trial
for Nano-Mupirocin and to advance the Nano-ARB program through IND-enabling studies, we may require additional funds beyond the net proceeds
of this offering. We intend to pursue such funding through additional financings, strategic partnerships, or non-dilutive sources such
as grants.

The use of the proceeds represents management’s
estimates based on current business and economic conditions. We will retain broad discretion over the use of the net proceeds of this
offering which may result in an allocation of net proceeds in differing amounts than those listed above, or in entirely new areas. The
amount and timing of these proposed expenditures will depend on a number of factors, including the progress product development programs,
and any unforeseen cash needs. As a result, you will be relying on the judgment of our management with regard to the use of these net
proceeds, and you will not have the opportunity, as part of your investment decision, to assess whether the proceeds are being used appropriately.
It is possible that the proceeds will be used in a way that does not yield a favorable, or any, return for us. Pending application of
the net proceeds as described above, we intend to invest the proceeds in investment grade interest bearing instruments or will hold the
proceeds in interest bearing or non-interest-bearing bank accounts.

<div align='center'>31

DETERMINATION OF THE OFFERING PRICE</div>

The offering price of the Units in the Primary
Offering has been determined arbitrarily by us. This price does not bear any relationship to our book value, earnings, or other established
criteria that would be evaluated for a company with an established public market. In determining the number of Units to be offered and
the offering price per unit, we took into consideration our cash on hand and the amount of money we would need to implement our business
plan. Accordingly, the offering price should not be considered an indication of the actual value of the securities. Unless and until
our Common Stock is listed on a